Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.

Molecular pharmaceutics - 4 Aug 2014

Sakurai Yu, Hatakeyama Hiroto, Akita Hidetaka, Harashima Hideyoshi

Abstract excerpt

It is well-known that renal cell carcinomas (RCCs) are resistant to classical cytotoxic anticancer drugs. Therefore, facilitating the impact of anticancer drugs by altering the cell phenotype should be a useful strategy for circumventing this. We developed a multifunctional envelope-type nanodevice (MEND) as an in vivo carrier of siRNA to tumor tissues. We previously reported that a MEND containing YSK05...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Doxorubicin
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Neoplasms

Share to Liposomes

Share to Nanotechnology

Share to Polo-Like Kinase 1

Share to RNA, Small Interfering

Source

Identifiers

PMID: 24800640
DOI: 10.1021/mp500245z

Genes

PLK1
CCNB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.PMID 24800640Read ↗

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.Semantic proximity Read ↗

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms.Semantic proximity Read ↗

PLK-1 Silencing in Bladder Cancer by siRNA Delivered With ExosomesSemantic proximity Read ↗

A Mechanistic Study on the Cellular Uptake, Intracellular Trafficking, and Antisense Gene Regulation of Bottlebrush Polymer-Conjugated OligonucleotidesSemantic proximity Read ↗

Cellular Uptake and Fate of Cationic Polymer-Coated Nanodiamonds Delivering siRNA: A Mechanistic StudySemantic proximity Read ↗

Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinomaSemantic proximity Read ↗

Active Liposomal Targeting for Head and Neck Squamous Cell Carcinoma TreatmentSemantic proximity Read ↗

Nanoformulated cell-penetrating survivin mutant and its dual actions.Semantic proximity Read ↗

Galactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In VivoSemantic proximity Read ↗

Antitumor Effects of N-Butylidenephthalide Encapsulated in Lipopolyplexs in Colorectal Cancer CellsSemantic proximity Read ↗

Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid CancerSemantic proximity Read ↗

Oxygen Nanocarrier Broke the Hypoxia Trap of Solid Tumors and Rescued Transfection Efficiency for Gene TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.